Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Man Pyo | - |
dc.contributor.author | Park, Moo Suk | - |
dc.contributor.author | Oh, In Jae | - |
dc.contributor.author | Lee, Heung Bum | - |
dc.contributor.author | Kim, Young Whan | - |
dc.contributor.author | Park, Jong Sun | - |
dc.contributor.author | Uh, Soo Taek | - |
dc.contributor.author | Kim, Yun Seong | - |
dc.contributor.author | Jegal, Yangjin | - |
dc.contributor.author | Song, Jin Woo | - |
dc.date.accessioned | 2021-09-10T06:50:29Z | - |
dc.date.available | 2021-09-10T06:50:29Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 0741-238X | - |
dc.identifier.issn | 1865-8652 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19534 | - |
dc.description.abstract | Aim The efficacy and safety of pirfenidone have been previously demonstrated in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF). However, the effect of pirfenidone in patients with advanced IPF remains unclear. Here, we investigated the effects of pirfenidone against advanced IPF in a real-world setting. Methods A prospective nationwide post-marketing study was conducted on 258 patients from 10 Korean institutions. Patients with a predicted forced vital capacity (FVC) less than 50% or a diffusing capacity of the lung for carbon monoxide (DLco) less than 35% at baseline were classified as the advanced IPF group. Results Of 219 patients included in the analysis, the majority were male (76.3%); the mean age was 67.3 years, and the advanced group accounted for 17.8% of the patients. The median treatment duration was 298 days. Among the subjects, 86.3% experienced adverse events (AEs), of which a decreased appetite (32.4%) and a photosensitivity reaction (13.7%) were the most frequent. The incidence of AEs was similar between the advanced and non-advanced groups (92.3% vs. 85.0%, respectively; p = 0.229). Although the overall discontinuation rate was higher in the advanced group than in the non-advanced group (74.4% vs. 50.0%, respectively; p = 0.006), the percentages of the patients who discontinued treatment as a result of AEs were similar in both groups (20.5% vs. 23.3%, respectively; p = 0.704). In all patients, the rates of decline in the predicted FVC and DLco over 48 weeks were - 4.3 +/- 1.3% and - 4.4 +/- 1.7%, respectively. There was no between-group difference in the rate of lung function decline. Conclusions Pirfenidone used for the treatment of patients with IPF in a real-world setting was well tolerated, with an acceptable safety profile and a consistent therapeutic effect, regardless of the disease severity. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Health Communications, Inc. | - |
dc.title | Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s12325-020-01328-8 | - |
dc.identifier.scopusid | 2-s2.0-85083449741 | - |
dc.identifier.wosid | 000526250900007 | - |
dc.identifier.bibliographicCitation | Advances in Therapy, v.37, no.5, pp 2303 - 2316 | - |
dc.citation.title | Advances in Therapy | - |
dc.citation.volume | 37 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 2303 | - |
dc.citation.endPage | 2316 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | FORCED VITAL CAPACITY | - |
dc.subject.keywordPlus | ACUTE EXACERBATION | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | STANDARDIZATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Advanced disease | - |
dc.subject.keywordAuthor | Disease progression | - |
dc.subject.keywordAuthor | Idiopathic pulmonary fibrosis | - |
dc.subject.keywordAuthor | Pirfenidone | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Treatment outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.